Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aerie Pharmaceuticals' Roclanda receives positive CHMP opinion in the EU » 06:52
11/13/20
11/13
06:52
11/13/20
06:52
AERI

Aerie Pharmaceuticals

$12.99 /

-0.06 (-0.46%)

Aerie Pharmaceuticals…

Aerie Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of the marketing authorisation application for Roclanda 0.02%/0.005%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. The CHMP positive opinion is a scientific recommendation for marketing authorisation, which is referred to the European Commission for a final decision on the company's MAA. The final decision is expected in approximately two months and will be applicable to all European Union member states plus Iceland, Norway and Liechtenstein. Roclanda is currently marketed as Rocklatan in the U.S. and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$12.99 /

-0.06 (-0.46%)

AERI Aerie Pharmaceuticals
$12.99 /

-0.06 (-0.46%)

11/09/20 H.C. Wainwright
Aerie Pharmaceuticals price target lowered to $29 from $31 at H.C. Wainwright
10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
AERI Aerie Pharmaceuticals
$12.99 /

-0.06 (-0.46%)

AERI Aerie Pharmaceuticals
$12.99 /

-0.06 (-0.46%)

Recommendations
Aerie Pharmaceuticals price target lowered to $29 from $31 at H.C. Wainwright » 06:11
11/09/20
11/09
06:11
11/09/20
06:11
AERI

Aerie Pharmaceuticals

$10.54 /

-0.19 (-1.77%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat lowered the firm's price target on Aerie Pharmaceuticals to $29 from $31 and keeps a Buy rating on the shares following the company's Q3 results.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$10.54 /

-0.19 (-1.77%)

AERI Aerie Pharmaceuticals
$10.54 /

-0.19 (-1.77%)

10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
AERI Aerie Pharmaceuticals
$10.54 /

-0.19 (-1.77%)

AERI Aerie Pharmaceuticals
$10.54 /

-0.19 (-1.77%)

Earnings
Aerie Pharmaceuticals reports Q3 EPS (86c), consensus (80c) » 16:06
11/05/20
11/05
16:06
11/05/20
16:06
AERI

Aerie Pharmaceuticals

$10.82 /

-0.08 (-0.73%)

Reports Q3 revenue…

Reports Q3 revenue $20.1M, consensus $19.7M. Net cash used in operating activities for the quarter ended September 30, 2020 on a U.S. GAAP basis totaled approximately $22.4 million, resulting in $218.4 million in cash and cash equivalents and investments as of September 30, 2020.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$10.82 /

-0.08 (-0.73%)

AERI Aerie Pharmaceuticals
$10.82 /

-0.08 (-0.73%)

10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
AERI Aerie Pharmaceuticals
$10.82 /

-0.08 (-0.73%)

AERI Aerie Pharmaceuticals
$10.82 /

-0.08 (-0.73%)

Hot Stocks
Aerie Pharmaceuticals initiates Phase 2b trial AR-15512 » 07:50
10/29/20
10/29
07:50
10/29/20
07:50
AERI

Aerie Pharmaceuticals

$10.29 /

+0.35 (+3.52%)

Aerie Pharmaceuticals…

Aerie Pharmaceuticals announced the commencement of COMET-1, a Phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of patients with dry eye disease. Topline results from COMET-1 are expected in the third quarter of 2021

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$10.29 /

+0.35 (+3.52%)

AERI Aerie Pharmaceuticals
$10.29 /

+0.35 (+3.52%)

10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
AERI Aerie Pharmaceuticals
$10.29 /

+0.35 (+3.52%)

AERI Aerie Pharmaceuticals
$10.29 /

+0.35 (+3.52%)

Recommendations
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright » 12:37
10/28/20
10/28
12:37
10/28/20
12:37
AERI

Aerie Pharmaceuticals

$10.31 /

+0.37 (+3.72%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat expects a "solid" Q3 for Aerie Pharmaceuticals against a "rough" sentiment backdrop. The analyst says the license agreement with Santen brings in a $50M upfront payment, plus milestones and royalties, adding that the news isn't surprising given Aerie has always telegraphed an eventual Japanese partnership. Livnat sees relatively low clinical risk in Japan given clearly positive Phase 2 data, sees a commercial launch in 2023 and thinks the $50M upfront should reduce sentiment overhang. The analyst made no change to his Buy rating.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$10.31 /

+0.37 (+3.72%)

AERI Aerie Pharmaceuticals
$10.31 /

+0.37 (+3.72%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
AERI Aerie Pharmaceuticals
$10.31 /

+0.37 (+3.72%)

AERI Aerie Pharmaceuticals
$10.31 /

+0.37 (+3.72%)

Hot Stocks
Aerie, Santen enter exclusive agreement for Rhopressa and Rocklatan in Japan » 05:12
10/28/20
10/28
05:12
10/28/20
05:12
AERI

Aerie Pharmaceuticals

$9.94 /

+0.17 (+1.74%)

Santen Pharmaceutical and…

Santen Pharmaceutical and Aerie Pharmaceuticals announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries. Rhopressa 0.02% and Rocklatan 0.02%/0.005% are approved and being sold in the United States by Aerie. Preparations for the first Phase 3 study in Japan for Rhopressa are ongoing and the study is expected to commence before the end of 2020. Under the terms of the agreement, Aerie will receive an upfront payment of $50M, and various development and sales milestones of up to $99M. Aerie is also eligible to receive additional consideration in excess of 25% of the products' net sales, such consideration consisting of the cost of products supplied to Santen from Aerie and a royalty for Aerie's intellectual property. Santen will be responsible for sales, marketing and pricing decisions relating to the products. Santen will also be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement, however, Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa in Japan. In addition to customary termination rights for both parties, in the event that patents are issued that may prevent the commercialization of the products, Santen would have the right to terminate the agreement and require Aerie's repayment of a portion of the upfront payment, all development milestone payments, and a portion of the development expenses incurred by Santen.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$9.94 /

+0.17 (+1.74%)

AERI Aerie Pharmaceuticals
$9.94 /

+0.17 (+1.74%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
AERI Aerie Pharmaceuticals
$9.94 /

+0.17 (+1.74%)

AERI Aerie Pharmaceuticals
$9.94 /

+0.17 (+1.74%)

Conference/Events
Mizuho pharmaceuticals analysts hold an analyst/industry conference call » 04:55
10/27/20
10/27
04:55
10/27/20
04:55
AERI

Aerie Pharmaceuticals

$9.80 /

-0.09 (-0.91%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts provide an updated view of the treatment paradigm for Glaucoma, Aerie Pharmaceuticals' Rhopressa and Rocklatan, on an Analyst/Industry conference call to be held on October 27.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$9.80 /

-0.09 (-0.91%)

AERI Aerie Pharmaceuticals
$9.80 /

-0.09 (-0.91%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
AERI Aerie Pharmaceuticals
$9.80 /

-0.09 (-0.91%)

AERI Aerie Pharmaceuticals
$9.80 /

-0.09 (-0.91%)

Over a month ago
Conference/Events
Mizuho pharmaceuticals analysts hold an analyst/industry conference call » 14:05
10/20/20
10/20
14:05
10/20/20
14:05
AERI

Aerie Pharmaceuticals

$9.35 /

-0.56 (-5.65%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts provide an updated view of the treatment paradigm for Glaucoma, Aerie Pharmaceuticals' Rhopressa and Rocklatan, on an Analyst/Industry conference call to be held on October 27.

ShowHide Related Items >><<
AERI Aerie Pharmaceuticals
$9.35 /

-0.56 (-5.65%)

AERI Aerie Pharmaceuticals
$9.35 /

-0.56 (-5.65%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
AERI Aerie Pharmaceuticals
$9.35 /

-0.56 (-5.65%)

AERI Aerie Pharmaceuticals
$9.35 /

-0.56 (-5.65%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:32
10/19/20
10/19
16:32
10/19/20
16:32
COP

ConocoPhillips

$32.70 /

-1.06 (-3.14%)

, CXO

Concho Resources

$47.27 /

-1.38 (-2.84%)

, AEL

American Equity

$27.51 /

-4.8 (-14.86%)

, ATH

Athene Holding

$34.46 /

-0.85 (-2.41%)

, BAM

Brookfield

$33.69 /

-0.04 (-0.12%)

, ARES

Ares Management

$44.45 /

-0.24 (-0.54%)

, INTC

Intel

$54.60 /

+0.43 (+0.79%)

, BSTC

BioSpecifics

$88.50 /

+27.43 (+44.92%)

, ENDP

Endo

$5.65 /

+0.665 (+13.34%)

, AERI

Aerie Pharmaceuticals

$9.91 /

-1.72 (-14.79%)

, MD

Mednax

$13.65 /

-1.22 (-8.20%)

, RESI

Front Yard Residential

$13.44 /

+3.5 (+35.21%)

, WDC

Western Digital

$40.93 /

+3 (+7.91%)

ShowHide Related Items >><<
WDC Western Digital
$40.93 /

+3 (+7.91%)

RESI Front Yard Residential
$13.44 /

+3.5 (+35.21%)

MD Mednax
$13.65 /

-1.22 (-8.20%)

INTC Intel
$54.60 /

+0.43 (+0.79%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$47.27 /

-1.38 (-2.84%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

BSTC BioSpecifics
$88.50 /

+27.43 (+44.92%)

BAM Brookfield
$33.69 /

-0.04 (-0.12%)

ATH Athene Holding
$34.46 /

-0.85 (-2.41%)

ARES Ares Management
$44.45 /

-0.24 (-0.54%)

AERI Aerie Pharmaceuticals
$9.91 /

-1.72 (-14.79%)

AEL American Equity
$27.51 /

-4.8 (-14.86%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

10/20/20 Morgan Stanley
Concho deal fortifies ConocoPhillips' leadership position, says Morgan Stanley
10/20/20 MKM Partners
Concho Resources downgraded to Neutral from Buy at MKM Partners
10/19/20
Fly Intel: Top five analyst downgrades
10/19/20 Wells Fargo
Concho Resources downgraded to Equal Weight from Overweight at Wells Fargo
CXO Concho Resources
$47.27 /

-1.38 (-2.84%)

AEL American Equity
$27.51 /

-4.8 (-14.86%)

10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
10/09/20 B. Riley Securities
American Equity price target raised to $30 from $23 at B. Riley Securities
10/09/20 Citi
American Equity price target raised to $31 from $25 at Citi
10/02/20 RBC Capital
American Equity upgraded to Outperform from Sector Perform at RBC Capital
ATH Athene Holding
$34.46 /

-0.85 (-2.41%)

06/22/20 BMO Capital
Athene Holding price target raised to $66 from $60 at BMO Capital
05/12/20 Truist
Athene Holding price target lowered to $45 from $61 at SunTrust
BAM Brookfield
$33.69 /

-0.04 (-0.12%)

10/19/20
Fly Intel: Top five analyst upgrades
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
08/17/20 Keefe Bruyette
Brookfield upgraded to Outperform from Market Perform at Keefe Bruyette
ARES Ares Management
$44.45 /

-0.24 (-0.54%)

05/28/20 BMO Capital
Ares Management upgraded to Outperform from Market Perform at BMO Capital
04/15/20 Wells Fargo
Ares Management price target lowered to $41 from $50 at Wells Fargo
02/18/20 RBC Capital
Ares Management price target raised to $45 from $38 at RBC Capital
02/18/20 BMO Capital
Ares Management price target raised to $41 from $34 at BMO Capital
INTC Intel
$54.60 /

+0.43 (+0.79%)

10/19/20 Lynx
Intel/SK Hynix deal impact to Western, Micron 'manageable,' says Lynx
10/19/20 Wells Fargo
Western Digital positive reaction to Intel report justifiable, says Wells Fargo
10/19/20 KeyBanc
Potential NAND business sale 'favorable' for Intel and sector, says KeyBanc
10/13/20 Mizuho
AMD price target raised to $90 from $77 at Mizuho
BSTC BioSpecifics
$88.50 /

+27.43 (+44.92%)

10/20/20 H.C. Wainwright
BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright
07/07/20 H.C. Wainwright
BioSpecifics price target raised to $100 from $90 at H.C. Wainwright
ENDP Endo
$5.65 /

+0.665 (+13.34%)

10/05/20 Piper Sandler
Piper reiterates Overweight on Endo after dermatologist survey
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
07/27/20 Goldman Sachs
Endo initiated with a Sell at Goldman Sachs
AERI Aerie Pharmaceuticals
$9.91 /

-1.72 (-14.79%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
MD Mednax
$13.65 /

-1.22 (-8.20%)

10/19/20 Deutsche Bank
Mednax downgraded to Sell from Hold at Deutsche Bank
06/09/20 Mizuho
Mednax price target raised to $20 from $17 at Mizuho
06/08/20 BMO Capital
Mednax price target raised to $20 from $16 at BMO Capital
RESI Front Yard Residential
$13.44 /

+3.5 (+35.21%)

10/20/20 Northland
Front Yard Residential downgraded to Market Perform from Outperform at Northland
10/20/20 JMP Securities
Front Yard Residential downgraded to Market Perform from Outperform at JMP Securities
10/20/20 Credit Suisse
Front Yard Residential downgraded to Neutral from Outperform at Credit Suisse
10/20/20 JMP Securities
Front Yard downgraded to Market Perform from Outperform at JMP Securities
WDC Western Digital
$40.93 /

+3 (+7.91%)

09/28/20 Deutsche Bank
Deutsche Bank closes 'Buy Catalyst Call' on Western Digital
WDC Western Digital
$40.93 /

+3 (+7.91%)

RESI Front Yard Residential
$13.44 /

+3.5 (+35.21%)

MD Mednax
$13.65 /

-1.22 (-8.20%)

INTC Intel
$54.60 /

+0.43 (+0.79%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$47.27 /

-1.38 (-2.84%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

BAM Brookfield
$33.69 /

-0.04 (-0.12%)

ATH Athene Holding
$34.46 /

-0.85 (-2.41%)

ARES Ares Management
$44.45 /

-0.24 (-0.54%)

AERI Aerie Pharmaceuticals
$9.91 /

-1.72 (-14.79%)

AEL American Equity
$27.51 /

-4.8 (-14.86%)

WDC Western Digital
$40.93 /

+3 (+7.91%)

INTC Intel
$54.60 /

+0.43 (+0.79%)

CXO Concho Resources
$47.27 /

-1.38 (-2.84%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

BAM Brookfield
$33.69 /

-0.04 (-0.12%)

AEL American Equity
$27.51 /

-4.8 (-14.86%)

WDC Western Digital
$40.93 /

+3 (+7.91%)

INTC Intel
$54.60 /

+0.43 (+0.79%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

BAM Brookfield
$33.69 /

-0.04 (-0.12%)

AERI Aerie Pharmaceuticals
$9.91 /

-1.72 (-14.79%)

AEL American Equity
$27.51 /

-4.8 (-14.86%)

WDC Western Digital
$40.93 /

+3 (+7.91%)

INTC Intel
$54.60 /

+0.43 (+0.79%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$47.27 /

-1.38 (-2.84%)

COP ConocoPhillips
$32.70 /

-1.06 (-3.14%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:25
10/19/20
10/19
12:25
10/19/20
12:25
COP

ConocoPhillips

$33.81 /

+0.05 (+0.15%)

, CXO

Concho Resources

$48.90 /

+0.25 (+0.51%)

, AEL

American Equity

$26.10 /

-6.21 (-19.22%)

, BAM

Brookfield

$34.30 /

+0.57 (+1.69%)

, RESI

Front Yard Residential

$13.50 /

+3.56 (+35.81%)

, TVTY

Tivity Health

$16.07 /

+0.66 (+4.28%)

, AMC

AMC Entertainment

$3.68 /

+0.645 (+21.25%)

, BSTC

BioSpecifics

$88.17 /

+27.1 (+44.38%)

, ENDP

Endo

$5.65 /

+0.665 (+13.34%)

, AERI

Aerie Pharmaceuticals

$10.05 /

-1.585 (-13.63%)

, MD

Mednax

$14.01 /

-0.865 (-5.82%)

The major averages have…

ShowHide Related Items >><<
TVTY Tivity Health
$16.07 /

+0.66 (+4.28%)

RESI Front Yard Residential
$13.50 /

+3.56 (+35.81%)

MD Mednax
$14.01 /

-0.865 (-5.82%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

BSTC BioSpecifics
$88.17 /

+27.1 (+44.38%)

BAM Brookfield
$34.30 /

+0.57 (+1.69%)

AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

AERI Aerie Pharmaceuticals
$10.05 /

-1.585 (-13.63%)

AEL American Equity
$26.10 /

-6.21 (-19.22%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

10/19/20
Fly Intel: Top five analyst downgrades
10/19/20 Wells Fargo
Concho Resources downgraded to Equal Weight from Overweight at Wells Fargo
10/14/20 RBC Capital
RBC says ConocoPhillips investors have favorable view of possible Concho deal
09/25/20
Fly Intel: Top five analyst initiations
CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

09/24/20 Scotiabank
Scotiabank adds EU super majors to coverage, shakes up oil ratings
AEL American Equity
$26.10 /

-6.21 (-19.22%)

10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
10/09/20 B. Riley Securities
American Equity price target raised to $30 from $23 at B. Riley Securities
10/09/20 Citi
American Equity price target raised to $31 from $25 at Citi
10/02/20 RBC Capital
American Equity upgraded to Outperform from Sector Perform at RBC Capital
BAM Brookfield
$34.30 /

+0.57 (+1.69%)

10/19/20
Fly Intel: Top five analyst upgrades
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
08/17/20 Keefe Bruyette
Brookfield upgraded to Outperform from Market Perform at Keefe Bruyette
RESI Front Yard Residential
$13.50 /

+3.56 (+35.81%)

10/19/20 JPMorgan
JPMorgan wouldn't be surprised to see 'some noise' on Front Yard deal price
06/12/20 Northland
Front Yard Residential upgraded to Outperform from Market Perform at Northland
06/08/20 JMP Securities
Front Yard upgraded to Outperform from Market Perform at JMP Securities
05/18/20 Credit Suisse
Front Yard Residential reinstated with an Outperform at Credit Suisse
TVTY Tivity Health
$16.07 /

+0.66 (+4.28%)

08/06/20 Craig-Hallum
Tivity Health upgraded to Buy at Craig-Hallum
08/06/20 Barrington
Tivity Health price target raised to $27 from $15 at Barrington
08/06/20 Craig-Hallum
Tivity Health upgraded to Buy from Hold at Craig-Hallum
06/12/20 Guggenheim
Tivity Health initiated with a Neutral at Guggenheim
AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

10/12/20 B. Riley Securities
AMC Entertainment price target lowered to $4.50 from $5.50 at B. Riley Securities
10/12/20 William Blair
William Blair suspends AMC Entertainment coverage due to uncertainty
09/14/20 B. Riley Securities
AMC Entertainment price target raised to $5.50 from $4 at B. Riley FBR
07/13/20 MKM Partners
MKM Partners lowers price targets in Cinema sector
BSTC BioSpecifics
$88.17 /

+27.1 (+44.38%)

07/07/20 H.C. Wainwright
BioSpecifics price target raised to $100 from $90 at H.C. Wainwright
ENDP Endo
$5.65 /

+0.665 (+13.34%)

10/05/20 Piper Sandler
Piper reiterates Overweight on Endo after dermatologist survey
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
07/27/20 Goldman Sachs
Endo initiated with a Sell at Goldman Sachs
06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
AERI Aerie Pharmaceuticals
$10.05 /

-1.585 (-13.63%)

10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Guggenheim
Aerie Pharmaceuticals initiated with a Buy at Guggenheim
MD Mednax
$14.01 /

-0.865 (-5.82%)

10/19/20 Deutsche Bank
Mednax downgraded to Sell from Hold at Deutsche Bank
06/09/20 Mizuho
Mednax price target raised to $20 from $17 at Mizuho
06/08/20 BMO Capital
Mednax price target raised to $20 from $16 at BMO Capital
TVTY Tivity Health
$16.07 /

+0.66 (+4.28%)

RESI Front Yard Residential
$13.50 /

+3.56 (+35.81%)

MD Mednax
$14.01 /

-0.865 (-5.82%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

BAM Brookfield
$34.30 /

+0.57 (+1.69%)

AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

AERI Aerie Pharmaceuticals
$10.05 /

-1.585 (-13.63%)

AEL American Equity
$26.10 /

-6.21 (-19.22%)

TVTY Tivity Health
$16.07 /

+0.66 (+4.28%)

CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

BAM Brookfield
$34.30 /

+0.57 (+1.69%)

AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

AEL American Equity
$26.10 /

-6.21 (-19.22%)

TVTY Tivity Health
$16.07 /

+0.66 (+4.28%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

BAM Brookfield
$34.30 /

+0.57 (+1.69%)

AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

AERI Aerie Pharmaceuticals
$10.05 /

-1.585 (-13.63%)

AEL American Equity
$26.10 /

-6.21 (-19.22%)

ENDP Endo
$5.65 /

+0.665 (+13.34%)

CXO Concho Resources
$48.90 /

+0.25 (+0.51%)

COP ConocoPhillips
$33.81 /

+0.05 (+0.15%)

AMC AMC Entertainment
$3.68 /

+0.645 (+21.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.